Michael Goggins

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11069427/publications.pdf

Version: 2024-02-01

227 papers	40,839 citations	2215 99 h-index	2448 197 g-index
234 all docs	234 docs citations	234 times ranked	36732 citing authors

#	Article	IF	Citations
1	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. Science, 2008, 321, 1801-1806.	12.6	3,755
2	Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies. Science Translational Medicine, 2014, 6, 224ra24.	12.4	3,665
3	Pancreatic cancer. Lancet, The, 2011, 378, 607-620.	13.7	2,155
4	An Illustrated Consensus on the Classification of Pancreatic Intraepithelial Neoplasia and Intraductal Papillary Mucinous Neoplasms. American Journal of Surgical Pathology, 2004, 28, 977-987.	3.7	964
5	Exomic Sequencing Identifies PALB2 as a Pancreatic Cancer Susceptibility Gene. Science, 2009, 324, 217-217.	12.6	713
6	Recurrent GNAS Mutations Define an Unexpected Pathway for Pancreatic Cyst Development. Science Translational Medicine, 2011, 3, 92ra66.	12.4	703
7	International Cancer of the Pancreas Screening (CAPS) Consortium summit on the management of patients with increased risk for familial pancreatic cancer. Gut, 2013, 62, 339-347.	12.1	672
8	A Revised Classification System and Recommendations From the Baltimore Consensus Meeting for Neoplastic Precursor Lesions in the Pancreas. American Journal of Surgical Pathology, 2015, 39, 1730-1741.	3.7	626
9	Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nature Genetics, 2009, 41, 986-990.	21.4	597
10	Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds. Cancer Research, 2004, 64, 2634-2638.	0.9	595
11	Frequent Detection of Pancreatic Lesions in Asymptomatic High-Risk Individuals. Gastroenterology, 2012, 142, 796-804.	1.3	570
12	Presence of Somatic Mutations in Most Early-Stage Pancreatic Intraepithelial Neoplasia. Gastroenterology, 2012, 142, 730-733.e9.	1.3	568
13	A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nature Genetics, 2010, 42, 224-228.	21.4	539
14	Detectable clonal mosaicism and its relationship to aging and cancer. Nature Genetics, 2012, 44, 651-658.	21.4	519
15	Screening for Early Pancreatic Neoplasia in High-Risk Individuals: A Prospective Controlled Study. Clinical Gastroenterology and Hepatology, 2006, 4, 766-781.	4.4	493
16	Exploration of Global Gene Expression Patterns in Pancreatic Adenocarcinoma Using cDNA Microarrays. American Journal of Pathology, 2003, 162, 1151-1162.	3.8	450
17	ATM Mutations in Patients with Hereditary Pancreatic Cancer. Cancer Discovery, 2012, 2, 41-46.	9.4	442
18	Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clinical Gastroenterology and Hepatology, 2004, 2, 606-621.	4.4	431

#	Article	IF	Citations
19	Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma. Journal of the National Cancer Institute, 2010, 102, 340-351.	6.3	392
20	Germline and Somatic Mutations of the STK11/LKB1 Peutz-Jeghers Gene in Pancreatic and Biliary Cancers. American Journal of Pathology, 1999, 154, 1835-1840.	3.8	380
21	A Combination of Molecular Markers and Clinical Features Improve the Classification of Pancreatic Cysts. Gastroenterology, 2015, 149, 1501-1510.	1.3	376
22	Peritumoral Fibroblast SPARC Expression and Patient Outcome With Resectable Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2007, 25, 319-325.	1.6	372
23	Management of patients with increased risk for familial pancreatic cancer: updated recommendations from the International Cancer of the Pancreas Screening (CAPS) Consortium. Gut, 2020, 69, 7-17.	12.1	357
24	Highly expressed genes in pancreatic ductal adenocarcinomas: a comprehensive characterization and comparison of the transcription profiles obtained from three major technologies. Cancer Research, 2003, 63, 8614-22.	0.9	336
25	SMAD4 Gene Mutations Are Associated with Poor Prognosis in Pancreatic Cancer. Clinical Cancer Research, 2009, 15, 4674-4679.	7.0	335
26	Deleterious Germline Mutations in Patients With Apparently Sporadic Pancreatic Adenocarcinoma. Journal of Clinical Oncology, 2017, 35, 3382-3390.	1.6	316
27	Mesothelin-specific CD8+ T Cell Responses Provide Evidence of In Vivo Cross-Priming by Antigen-Presenting Cells in Vaccinated Pancreatic Cancer Patients. Journal of Experimental Medicine, 2004, 200, 297-306.	8.5	314
28	NCCN Guidelines Insights: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 1.2020. Journal of the National Comprehensive Cancer Network: JNCCN, 2020, 18, 380-391.	4.9	314
29	Targeted nextâ€generation sequencing of cancer genes dissects the molecular profiles of intraductal papillary neoplasms of the pancreas. Journal of Pathology, 2014, 233, 217-227.	4.5	308
30	The deubiquitinase USP9X suppresses pancreatic ductal adenocarcinoma. Nature, 2012, 486, 266-270.	27.8	297
31	Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. Nature Genetics, 2014, 46, 994-1000.	21.4	294
32	Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. Gastroenterology, 2018, 155, 740-751.e2.	1.3	288
33	Whole Genome Sequencing Defines the Genetic Heterogeneity of Familial Pancreatic Cancer. Cancer Discovery, 2016, 6, 166-175.	9.4	282
34	MicroRNA Array Analysis Finds Elevated Serum miR-1290 Accurately Distinguishes Patients with Low-Stage Pancreatic Cancer from Healthy and Disease Controls. Clinical Cancer Research, 2013, 19, 3600-3610.	7.0	279
35	A Systematic Review of Solid-Pseudopapillary Neoplasms. Pancreas, 2014, 43, 331-337.	1.1	276
36	Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry. Clinical Cancer Research, 2004, 10, 860-868.	7.0	273

#	Article	IF	Citations
37	Discovery of Novel Tumor Markers of Pancreatic Cancer using Global Gene Expression Technology. American Journal of Pathology, 2002, 160, 1239-1249.	3.8	271
38	Pancreatic cancer. Current Problems in Cancer, 2002, 26, 176-275.	2.0	268
39	Pancreatic Cancers Epigenetically Silence SIP1 and Hypomethylate and Overexpress miR-200a/200b in Association with Elevated Circulating miR-200a and miR-200b Levels. Cancer Research, 2010, 70, 5226-5237.	0.9	268
40	Discovery of novel targets for aberrant methylation in pancreatic carcinoma using high-throughput microarrays. Cancer Research, 2003, 63, 3735-42.	0.9	267
41	Genetic, Immunohistochemical, and Clinical Features of Medullary Carcinoma of the Pancreas. American Journal of Pathology, 2000, 156, 1641-1651.	3.8	263
42	SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumorâ€“stromal interactions. Oncogene, 2003, 22, 5021-5030.	5.9	263
43	Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types. Human Mutation, 2012, 33, 100-103.	2.5	263
44	Multifocal neoplastic precursor lesions associated with lobular atrophy of the pancreas in patients having a strong family history of pancreatic cancer. American Journal of Surgical Pathology, 2006, 30, 1067-76.	3.7	261
45	The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2007, 16, 342-346.	2.5	255
46	STK11/LKB1 Peutz-Jeghers Gene Inactivation in Intraductal Papillary-Mucinous Neoplasms of the Pancreas. American Journal of Pathology, 2001, 159, 2017-2022.	3.8	251
47	Serum Macrophage Inhibitory Cytokine 1 as a Marker of Pancreatic and Other Periampullary Cancers. Clinical Cancer Research, 2004, 10, 2386-2392.	7.0	250
48	Frequent hypomethylation of multiple genes overexpressed in pancreatic ductal adenocarcinoma. Cancer Research, 2003, 63, 4158-66.	0.9	238
49	Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. Cancer Research, 2002, 62, 1868-75.	0.9	233
50	Update on Familial Pancreatic Cancer. Advances in Surgery, 2010, 44, 293-311.	1.3	224
51	Common variation at 2p13.3, 3q29, 7p13 and 17q25.1 associated with susceptibility to pancreatic cancer. Nature Genetics, 2015, 47, 911-916.	21.4	224
52	Gene Expression Profiles in Pancreatic Intraepithelial Neoplasia Reflect the Effects of Hedgehog Signaling on Pancreatic Ductal Epithelial Cells. Cancer Research, 2005, 65, 1619-1626.	0.9	223
53	Phenotypic variation in eight extendedCDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families. Cancer, 2002, 94, 84-96.	4.1	221
54	The Human MitoChip: A High-Throughput Sequencing Microarray for Mitochondrial Mutation Detection. Genome Research, 2004, 14, 812-819.	5.5	218

#	Article	IF	Citations
55	Molecular Markers of Early Pancreatic Cancer. Journal of Clinical Oncology, 2005, 23, 4524-4531.	1.6	212
56	DNA Methylation Alterations in the Pancreatic Juice of Patients with Suspected Pancreatic Disease. Cancer Research, 2006, 66, 1208-1217.	0.9	207
57	The Early Detection of Pancreatic Cancer: What Will It Take to Diagnose and Treat Curable Pancreatic Neoplasia?. Cancer Research, 2014, 74, 3381-3389.	0.9	207
58	Aberrant Methylation of Preproenkephalin and p16 Genes in Pancreatic Intraepithelial Neoplasia and Pancreatic Ductal Adenocarcinoma. American Journal of Pathology, 2002, 160, 1573-1581.	3.8	205
59	Overexpression of S100A4 in Pancreatic Ductal Adenocarcinomas Is Associated with Poor Differentiation and DNA Hypomethylation. American Journal of Pathology, 2002, 160, 45-50.	3.8	203
60	MicroRNA Alterations of Pancreatic Intraepithelial Neoplasias. Clinical Cancer Research, 2012, 18, 981-992.	7.0	198
61	Serum Markers in Patients with Resectable Pancreatic Adenocarcinoma: Macrophage Inhibitory Cytokine 1 versus CA19-9. Clinical Cancer Research, 2006, 12, 442-446.	7.0	197
62	Increased Prevalence of Precursor Lesions in Familial Pancreatic Cancer Patients. Clinical Cancer Research, 2009, 15, 7737-7743.	7.0	195
63	BRCA2 Is Inactivated Late in the Development of Pancreatic Intraepithelial Neoplasia. American Journal of Pathology, 2000, 156, 1767-1771.	3.8	192
64	Gene Expression Profiling Identifies Genes Associated with Invasive Intraductal Papillary Mucinous Neoplasms of the Pancreas. American Journal of Pathology, 2004, 164, 903-914.	3.8	190
65	Genome-wide meta-analysis identifies five new susceptibility loci for pancreatic cancer. Nature Communications, 2018, 9, 556.	12.8	188
66	Precursors to Pancreatic Cancer. Gastroenterology Clinics of North America, 2007, 36, 831-849.	2.2	174
67	Genome-wide profiling at methylated promoters in pancreatic adenocarcinoma. Cancer Biology and Therapy, 2008, 7, 1146-1156.	3.4	165
68	MutantGNASdetected in duodenal collections of secretin-stimulated pancreatic juice indicates the presence or emergence of pancreatic cysts. Gut, 2013, 62, 1024-1033.	12.1	160
69	Overexpression of Smoothened Activates the Sonic Hedgehog Signaling Pathway in Pancreatic Cancerâ€“Associated Fibroblasts. Clinical Cancer Research, 2010, 16, 1781-1789.	7.0	159
70	Update on pancreatic intraepithelial neoplasia. International Journal of Clinical and Experimental Pathology, 2008, 1, 306-16.	0.5	159
71	Time to progression of pancreatic ductal adenocarcinoma from low-to-high tumour stages. Gut, 2015, 64, 1783-1789.	12.1	157
72	Identification of maspin and S100P as novel hypomethylation targets in pancreatic cancer using global gene expression profiling. Oncogene, 2004, 23, 1531-1538.	5.9	154

#	Article	IF	Citations
73	Genome-Wide Analysis of Promoter Methylation Associated with Gene Expression Profile in Pancreatic Adenocarcinoma. Clinical Cancer Research, 2011, 17, 4341-4354.	7.0	154
74	Mutant TP53 in Duodenal Samples of Pancreatic Juice From Patients With Pancreatic Cancer or High-Grade Dysplasia. Clinical Gastroenterology and Hepatology, 2013, 11, 719-730.e5.	4.4	154
75	Analysis of Heritability and Shared Heritability Based on Genome-Wide Association Studies for Thirteen Cancer Types. Journal of the National Cancer Institute, 2015, 107, djv279.	6.3	152
76	Gene Expression Profiling of Tumorâ€"Stromal Interactions between Pancreatic Cancer Cells and Stromal Fibroblasts. Cancer Research, 2004, 64, 6950-6956.	0.9	145
77	Epigenetic inactivation of TFPI-2 as a common mechanism associated with growth and invasion of pancreatic ductal adenocarcinoma. Oncogene, 2005, 24, 850-858.	5.9	144
78	Inhibiting the Cyclin-Dependent Kinase CDK5 Blocks Pancreatic Cancer Formation and Progression through the Suppression of Ras-Ral Signaling. Cancer Research, 2010, 70, 4460-4469.	0.9	140
79	Differential and Epigenetic Gene Expression Profiling Identifies Frequent Disruption of the RELN Pathway in Pancreatic Cancers. Gastroenterology, 2006, 130, 548-565.	1.3	139
80	Evaluating Susceptibility to Pancreatic Cancer: ASCO Provisional Clinical Opinion. Journal of Clinical Oncology, 2019, 37, 153-164.	1.6	135
81	Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms. Gut, 2017, 66, 1677-1687.	12.1	134
82	Pancreatic Cancer Genetic Epidemiology Consortium. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 704-710.	2.5	133
83	Early detection of pancreatic carcinoma. Hematology/Oncology Clinics of North America, 2002, 16, 37-52.	2.2	130
84	Molecular Signatures of Pancreatic Cancer. Archives of Pathology and Laboratory Medicine, 2011, 135, 716-727.	2.5	130
85	Genetic Mutations Associated with Cigarette Smoking in Pancreatic Cancer. Cancer Research, 2009, 69, 3681-3688.	0.9	126
86	Immunohistochemical Validation of a Novel Epithelial and a Novel Stromal Marker of Pancreatic Ductal Adenocarcinoma Identified by Global Expression Microarrays. American Journal of Clinical Pathology, 2002, 118, 52-59.	0.7	124
87	Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology, 2002, 123, 365-372.	1.3	124
88	New Markers of Pancreatic Cancer Identified Through Differential Gene Expression Analyses: Claudin 18 and Annexin A8. American Journal of Surgical Pathology, 2008, 32, 188-196.	3.7	121
89	An Absolute Risk Model to Identify Individuals at Elevated Risk for Pancreatic Cancer in the General Population. PLoS ONE, 2013, 8, e72311.	2.5	120
90	CpG island methylation profile of pancreatic intraepithelial neoplasia. Modern Pathology, 2008, 21, 238-244.	5.5	119

#	Article	IF	Citations
91	Recent Trends in the Incidence and Survival of Stage 1A Pancreatic Cancer: A Surveillance, Epidemiology, and End Results Analysis. Journal of the National Cancer Institute, 2020, 112, 1162-1169.	6.3	114
92	Aberrant Methylation of the 5' CpG Island of TSLC1 Is Common in Pancreatic Ductal Adenocarcinoma and Is First Manifest in High-Grade PanINs. Cancer Biology and Therapy, 2002, 1, 293-296.	3.4	112
93	Epigenetic Down-Regulation of CDKN1C/p57KIP2 in Pancreatic Ductal Neoplasms Identified by Gene Expression Profiling. Clinical Cancer Research, 2005, 11, 4681-4688.	7.0	108
94	Diagnosing Pancreatic Cancer Using Methylation Specific PCR Analysis. Cancer Biology and Therapy, 2003, 2, 79-84.	3.4	107
95	Effects of 5-Aza-2'-deoxycytidine on Matrix Metalloproteinase Expression and Pancreatic Cancer Cell Invasiveness. Journal of the National Cancer Institute, 2003, 95, 327-330.	6.3	106
96	Role of hyaluronan in pancreatic cancer biology and therapy: Once again in the spotlight. Cancer Science, 2016, 107, 569-575.	3.9	106
97	Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas. Annals of Surgery, 2017, 266, 133-141.	4.2	106
98	Loss of Stk11/Lkb1 Expression in Pancreatic and Biliary Neoplasms. Modern Pathology, 2003, 16, 686-691.	5.5	104
99	p16 Inactivation in Pancreatic Intraepithelial Neoplasias (PanINs) Arising in Patients With Chronic Pancreatitis. American Journal of Surgical Pathology, 2003, 27, 1495-1501.	3.7	104
100	Characterization of gene expression in mucinous cystic neoplasms of the pancreas using oligonucleotide microarrays. Oncogene, 2004, 23, 9042-9051.	5.9	103
101	Lactate-mediated epigenetic reprogramming regulates formation of human pancreatic cancer-associated fibroblasts. ELife, 2019, 8, .	6.0	103
102	Pathway analysis of genome-wide association study data highlights pancreatic development genes as susceptibility factors for pancreatic cancer. Carcinogenesis, 2012, 33, 1384-1390.	2.8	102
103	Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion. Modern Pathology, 2005, 18, 959-963.	5.5	101
104	The Chemokine Receptor CXCR4 is Regulated by DNA Methylation in Pancreatic Cancer. Cancer Biology and Therapy, 2005, 4, 77-83.	3.4	100
105	KRAS2 Mutations in Human Pancreatic Acinar-Ductal Metaplastic Lesions Are Limited to Those with PanIN: Implications for the Human Pancreatic Cancer Cell of Origin. Molecular Cancer Research, 2009, 7, 230-236.	3.4	98
106	Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas. Cancer Cell, 2017, 32, 824-839.e8.	16.8	97
107	Circulating Tumor Cells Expressing Markers of Tumor-Initiating Cells Predict Poor Survival and Cancer Recurrence in Patients with Pancreatic Ductal Adenocarcinoma. Clinical Cancer Research, 2017, 23, 2681-2690.	7.0	91
108	Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Modern Pathology, 2011, 24, 1237-1247.	5.5	90

#	Article	IF	Citations
109	Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Human Molecular Genetics, 2014, 23, 6616-6633.	2.9	90
110	Identifying Molecular Markers for the Early Detection of Pancreatic Neoplasia. Seminars in Oncology, 2007, 34, 303-310.	2.2	89
111	Three new pancreatic cancer susceptibility signals identified on chromosomes 1q32.1, 5p15.33 and 8q24.21. Oncotarget, 2016, 7, 66328-66343.	1.8	88
112	Aberrant methylation of the human hedgehog interacting protein (HHIP) gene in pancreatic neoplasms. Cancer Biology and Therapy, 2005, 4, 728-733.	3.4	83
113	The role of epigenetic alterations in pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Surgery, 2006, 13, 286-295.	2.0	83
114	Serum Fatty Acid Synthase as a Marker of Pancreatic Neoplasia. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2380-2385.	2.5	81
115	Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis. Clinical Cancer Research, 2014, 20, 1865-1872.	7.0	81
116	Multiple genes are hypermethylated in intraductal papillary mucinous neoplasms of the pancreas. Modern Pathology, 2008, 21, 1499-1507.	5.5	79
117	Genetic and Epigenetic Alterations of Familial Pancreatic Cancers. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3536-3542.	2.5	79
118	The Genetics ofFANCCandFANCGin Familial Pancreatic Cancer. Cancer Biology and Therapy, 2004, 3, 167-169.	3.4	78
119	Pancreatic cancer associated fibroblasts display normal allelotypes. Cancer Biology and Therapy, 2008, 7, 882-888.	3.4	76
120	KRAS and Guanine Nucleotide-Binding Protein Mutations in Pancreatic Juice Collected From the Duodenum of Patients at High Risk for Neoplasia Undergoing Endoscopic Ultrasound. Clinical Gastroenterology and Hepatology, 2015, 13, 963-969.e4.	4.4	74
121	Differentially expressed genes in pancreatic ductal adenocarcinomas identified through serial analysis of gene expression. Cancer Biology and Therapy, 2004, 3, 1254-1261.	3.4	73
122	DNA Methylation Alterations In Endoscopic Retrograde Cholangiopancreatography Brush Samples of Patients With Suspected Pancreaticobiliary Disease. Clinical Gastroenterology and Hepatology, 2008, 6, 1270-1278.	4.4	73
123	Genome-Wide CpG Island Profiling of Intraductal Papillary Mucinous Neoplasms of the Pancreas. Clinical Cancer Research, 2012, 18, 700-712.	7.0	69
124	The Multicenter Cancer of Pancreas Screening Study: Impact on Stage and Survival. Journal of Clinical Oncology, 2022, 40, 3257-3266.	1.6	69
125	Increased prevalence of the BRCA2 polymorphic stop codon K3326X among individuals with familial pancreatic cancer. Oncogene, 2005, 24, 3652-3656.	5.9	68
126	Gene expression alterations in the non-neoplastic parenchyma adjacent to infiltrating pancreatic ductal adenocarcinoma. Modern Pathology, 2005, 18, 779-787.	5.5	66

#	Article	IF	Citations
127	Elevated Cancer Mortality in the Relatives of Patients with Pancreatic Cancer. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2829-2834.	2.5	65
128	Mutations in the pancreatic secretory enzymes CPA1 and CPB1 are associated with pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, 4767-4772.	7.1	65
129	Deleterious Germline Mutations Are a Risk Factor for Neoplastic Progression Among High-Risk Individuals Undergoing Pancreatic Surveillance. Journal of Clinical Oncology, 2019, 37, 1070-1080.	1.6	65
130	Clinical importance of precursor lesions in the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery, 2007, 14, 255-263.	2.0	64
131	Pathological and Molecular Evaluation of Pancreatic Neoplasms. Seminars in Oncology, 2015, 42, 28-39.	2.2	64
132	Pancreatic Juice Exosomal MicroRNAs as Biomarkers for Detection of Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2019, 26, 2104-2111.	1.5	64
133	Tumor COX-2 expression and prognosis of patients with resectable pancreatic cancer. Cancer Biology and Therapy, 2007, 6, 1569-1575.	3.4	63
134	Olaparib in combination with irinotecan, cisplatin, and mitomycin C in patients with advanced pancreatic cancer. Oncotarget, 2017, 8, 44073-44081.	1.8	63
135	Can we screen high-risk individuals to detect early pancreatic carcinoma?. Journal of Surgical Oncology, 2000, 74, 243-248.	1.7	62
136	Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer. Annals of Surgical Oncology, 2011, 18, 3493-3499.	1.5	62
137	BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma. Journal of the American College of Surgeons, 2018, 226, 630-637e1.	0.5	62
138	A Transcriptome-Wide Association Study Identifies Novel Candidate Susceptibility Genes for Pancreatic Cancer. Journal of the National Cancer Institute, 2020, 112, 1003-1012.	6.3	59
139	Increased Cyclooxygenase-2 Expression in Duodenal Compared with Colonic Tissues in Familial Adenomatous Polyposis and Relationship to the â^'765G â†' C COX-2 Polymorphism. Clinical Cancer Research, 2005, 11, 4090-4096.	7.0	58
140	Loss of expression of the SWI/SNF chromatin remodeling subunit BRG1/SMARCA4 is frequently observed in intraductal papillary mucinous neoplasms of the pancreas. Human Pathology, 2012, 43, 585-591.	2.0	56
141	Pancreatic Juice Mutation Concentrations Can Help Predict the Grade of Dysplasia in Patients Undergoing Pancreatic Surveillance. Clinical Cancer Research, 2018, 24, 2963-2974.	7.0	55
142	Pancreatic cancerDNMT1expression and sensitivity toDNMT1inhibitors. Cancer Biology and Therapy, 2010, 9, 321-329.	3.4	54
143	Epigenetics and epigenetic alterations in pancreatic cancer. International Journal of Clinical and Experimental Pathology, 2009, 2, 310-26.	0.5	54
144	Identification of novel highly expressed genes in pancreatic ductal adenocarcinomas through a bioinformatics analysis of expressed sequence tags. Cancer Biology and Therapy, 2004, 3, 1081-1089.	3.4	52

#	Article	IF	Citations
145	Genome-Wide Allelotypes of Familial Pancreatic Adenocarcinomas and Familial and Sporadic Intraductal Papillary Mucinous Neoplasms. Clinical Cancer Research, 2007, 13, 6019-6025.	7.0	52
146	Palladin is overexpressed in the non-neoplastic stroma of infiltrating ductal adenocarcinomas of the pancreas, but is only rarely overexpressed in neoplastic cells. Cancer Biology and Therapy, 2007, 6, 324-328.	3.4	50
147	Absence of germline BRCA1 mutations in familial pancreatic cancer patients. Cancer Biology and Therapy, 2009, 8, 131-135.	3.4	50
148	Aberrant CpG island methylation in cancer cell lines arises in the primary cancers from which they were derived. Oncogene, 2002, 21, 2114-2117.	5.9	49
149	Differentiating pancreatic lesions by microarray and QPCR analysis of pancreatic juice RNAs. Cancer Biology and Therapy, 2006, 5, 1383-1389.	3.4	48
150	Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms. Gastroenterology, 2019, 156, 1905-1913.	1.3	47
151	Detection of Early-Stage Pancreatic Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 2786-2794.	2.5	45
152	Role of a Multidisciplinary Clinic in the Management of Patients with Pancreatic Cysts: A Single-Center Cohort Study. Annals of Surgical Oncology, 2014, 21, 3668-3674.	1.5	45
153	Epigenetic alterations in intraductal papillary mucinous neoplasms of the pancreas. Journal of Hepato-Biliary-Pancreatic Surgery, 2006, 13, 280-285.	2.0	44
154	Vascular Invasion in Infiltrating Ductal Adenocarcinoma of the Pancreas Can Mimic Pancreatic Intraepithelial Neoplasia. American Journal of Surgical Pathology, 2012, 36, 235-241.	3.7	44
155	Aberrant methylation ofReprimo correlates with genetic instability and predicts poor prognosis in pancreatic ductal adenocarcinoma. Cancer, 2006, 107, 251-257.	4.1	43
156	Genome-Wide Somatic Copy Number Alterations in Low-Grade PanINs and IPMNs from Individuals with a Family History of Pancreatic Cancer. Clinical Cancer Research, 2012, 18, 4303-4312.	7.0	43
157	Allele-specific expression in the germline of patients with familial pancreatic cancer: An unbiased approach to cancer gene discovery. Cancer Biology and Therapy, 2008, 7, 135-144.	3.4	42
158	Tumor-Suppressor genes in pancreatic cancer. Journal of Hepato-Biliary-Pancreatic Surgery, 1998, 5, 383-391.	2.0	40
159	Pancreaticobiliary Cancers With Deficient Methylenetetrahydrofolate Reductase Genotypes. Clinical Gastroenterology and Hepatology, 2005, 3, 752-760.	4.4	40
160	Absence of Deleterious Palladin Mutations in Patients with Familial Pancreatic Cancer: Table 1.. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 1328-1330.	2.5	39
161	Markers of Pancreatic Cancer: Working Toward Early Detection. Clinical Cancer Research, 2011, 17, 635-637.	7.0	39
162	PAM4 enzyme immunoassay alone and in combination with CA 19â€9 for the detection of pancreatic adenocarcinoma. Cancer, 2013, 119, 522-528.	4.1	38

#	Article	IF	Citations
163	Copy-number variants in patients with a strong family history of pancreatic cancer. Cancer Biology and Therapy, 2007, 6, 1592-1599.	3.4	36
164	Risk Factors of Familial Pancreatic Cancer in Japan. Pancreas, 2011, 40, 974-978.	1.1	36
165	Gene expression profiling identifies markers of ampullary adenocarcinoma. Cancer Biology and Therapy, 2004, 3, 651-656.	3.4	35
166	Telomeres are shortened in acinar-to-ductal metaplasia lesions associated with pancreatic intraepithelial neoplasia but not in isolated acinar-to-ductal metaplasias. Modern Pathology, 2011, 24, 256-266.	5.5	34
167	A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts. Journal of the American Medical Informatics Association: JAMIA, 2017, 24, 145-152.	4.4	34
168	A histomorphologic comparison of familial and sporadic pancreatic cancers. Pancreatology, 2015, 15, 387-391.	1.1	32
169	Genome-Wide Somatic Copy Number Alterations and Mutations in High-Grade Pancreatic Intraepithelial Neoplasia. American Journal of Pathology, 2018, 188, 1723-1733.	3.8	32
170	Real-time detection of mesothelin in pancreatic cancer cell line supernatant using an acoustic wave immunosensor. Cancer Detection and Prevention, 2006, 30, 180-187.	2.1	31
171	Gene Variants That Affect Levels of Circulating Tumor Markers Increase Identification of Patients With Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2020, 18, 1161-1169.e5.	4.4	31
172	Genetic counseling and testing for germline p16 mutations in two pancreatic cancerâ€“prone families. Gastroenterology, 2000, 119, 1756-1760.	1.3	30
173	Molecular characterization of organoids derived from pancreatic intraductal papillary mucinous neoplasms. Journal of Pathology, 2020, 252, 252-262.	4.5	30
174	Vitamin D Metabolic Pathway Genes and Pancreatic Cancer Risk. PLoS ONE, 2015, 10, e0117574.	2.5	29
175	p120 Catenin Suppresses Basal Epithelial Cell Extrusion in Invasive Pancreatic Neoplasia. Cancer Research, 2016, 76, 3351-3363.	0.9	29
176	Epigenetic silencing of EYA2 in pancreatic adenocarcinomas promotes tumor growth. Oncotarget, 2014, 5, 2575-2587.	1.8	29
177	Mutant KRAS and GNAS DNA Concentrations in Secretin-Stimulated Pancreatic Fluid Collected from the Pancreatic Duct and the Duodenal Lumen. Clinical and Translational Gastroenterology, 2014, 5, e62.	2.5	28
178	Cyclooxygenase-Deficient Pancreatic Cancer Cells Use Exogenous Sources of Prostaglandins. Molecular Cancer Research, 2010, 8, 821-832.	3.4	27
179	Nuclear Localization of Dpc4 (Madh4, Smad4) in Colorectal Carcinomas and Relation to Mismatch Repair/Transforming Growth Factor-Î² Receptor Defects. American Journal of Pathology, 2001, 158, 537-542.	3.8	25
180	Expression and prognostic significance of 14-3-3 sigma and ERM family protein expression in periampullary neoplasms. Cancer Biology and Therapy, 2005, 4, 596-601.	3.4	24

#	Article	IF	Citations
181	Unlike Pancreatic Cancer Cells Pancreatic Cancer Associated Fibroblasts Display Minimal Gene Induction after 5-Aza-2â€²-Deoxycytidine. PLoS ONE, 2012, 7, e43456.	2.5	24
182	Susceptibility of ATM-deficient pancreatic cancer cells to radiation. Cell Cycle, 2017, 16, 991-998.	2.6	24
183	Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. Modern Pathology, 2019, 32, 1806-1813.	5.5	21
184	Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. Modern Pathology, 2019, 32, 659-665.	5.5	20
185	Molecular genetics and related developments in pancreatic cancer. Current Opinion in Gastroenterology, 1999, 15, 404.	2.3	20
186	Detecting low-abundance p16 and p53 mutations in pancreatic juice using a novel assay: Heteroduplex analysis of limiting dilution PCRs. Cancer Biology and Therapy, 2006, 5, 1392-1399.	3.4	19
187	Incremental value of secretin-enhanced magnetic resonance cholangiopancreatography in detecting ductal communication in a population with high prevalence of small pancreatic cysts. European Journal of Radiology, 2015, 84, 575-580.	2.6	19
188	Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing. Cancer Letters, 2020, 493, 245-253.	7.2	18
189	Overexpression of ankyrin1 promotes pancreatic cancer cell growth. Oncotarget, 2016, 7, 34977-34987.	1.8	18
190	Amplification of EMSY gene in a subset of sporadic pancreatic adenocarcinomas. International Journal of Clinical and Experimental Pathology, 2008, 1, 343-51.	0.5	18
191	Familial pancreatic cancer: from genes to improved patient care. Expert Review of Gastroenterology and Hepatology, 2007, 1, 81-88.	3.0	16
192	Simple Detection of Telomere Fusions in Pancreatic Cancer, Intraductal Papillary Mucinous Neoplasm, and Pancreatic Cyst Fluid. Journal of Molecular Diagnostics, 2018, 20, 46-55.	2.8	16
193	Inherited Pancreatic Cancer Syndromes and High-Risk Screening. Surgical Oncology Clinics of North America, 2021, 30, 773-786.	1.5	16
194	Obstructive Sleep Apnea and Pathological Characteristics of Resected Pancreatic Ductal Adenocarcinoma. PLoS ONE, 2016, 11, e0164195.	2.5	15
195	Duodenal Involvement is an Independent Prognostic Factor for Patients with Surgically Resected Pancreatic Ductal Adenocarcinoma. Annals of Surgical Oncology, 2017, 24, 2379-2386.	1.5	14
196	IL2RG, identified as overexpressed by RNA-seq profiling of pancreatic intraepithelial neoplasia, mediates pancreatic cancer growth. Oncotarget, 2017, 8, 83370-83383.	1.8	14
197	Emerging molecular biology of pancreatic cancer. Gastrointestinal Cancer Research: GCR, 2008, 2, S10-5.	0.7	14
198	Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements. Journal of Molecular Diagnostics, 2019, 21, 658-676.	2.8	13

#	Article	IF	Citations
199	Serum miR-1290 as a Marker of Pancreatic Cancerâ€"Response. Clinical Cancer Research, 2013, 19, 5252-5253.	7.0	12
200	Identification of Differentially Expressed Proteins in Pancreatic Cancer Using a Global Proteomic Approach. , 2005, 103, 189-198.		11
201	The Effect of Pancreatic Juice Collection Time on the Detection of KRAS Mutations. Pancreas, 2018, 47, 35-39.	1.1	11
202	Detection of Circulating Tumor DNA in Patients with Pancreatic Cancer Using Digital Next-Generation Sequencing. Journal of Molecular Diagnostics, 2020, 22, 748-756.	2.8	11
203	Lack of association between the pancreatitis risk allele CEL-HYB and pancreatic cancer. Oncotarget, 2017, 8, 50824-50831.	1.8	11
204	Endoplasmic stressâ€inducing variants in <scp>CPB1</scp> and <scp>CPA1</scp> and risk of pancreatic cancer: A caseâ€control study and metaâ€analysis. International Journal of Cancer, 2022, 150, 1123-1133.	5.1	11
205	Using an endoscopic distal cap to collect pancreatic fluid fromÂthe ampulla (with video). Gastrointestinal Endoscopy, 2017, 86, 1152-1156.e2.	1.0	10
206	GLP-1 Receptor Agonist Effects on Normal and Neoplastic Pancreata. Diabetes, 2012, 61, 989-990.	0.6	9
207	DNA Methylation Analysis in Human Cancer. Methods in Molecular Biology, 2013, 980, 131-156.	0.9	8
208	Classifying pancreatic cancer using gene expression profiling. Nature Reviews Gastroenterology and Hepatology, 2015, 12, 613-614.	17.8	8
209	Blood Type as a Predictor of High-Grade Dysplasia and Associated Malignancy in Patients with Intraductal Papillary Mucinous Neoplasms. Journal of Gastrointestinal Surgery, 2019, 23, 477-483.	1.7	8
210	COVID-19 related pancreatic cancer surveillance disruptions amongst high-risk individuals. Pancreatology, 2021, 21, 1048-1051.	1.1	8
211	Serum Carboxypeptidase Activity and Genotype-Stratified CA19-9 to Detect Early-Stage Pancreatic Cancer. Clinical Gastroenterology and Hepatology, 2022, 20, 2267-2275.e2.	4.4	8
212	Liver transplant patients have a similar risk of progression as sporadic patients with branch duct intraductal papillary mucinous neoplasms. Liver Transplantation, 2014, 20, n/a-n/a.	2.4	7
213	Diagnostic and Therapeutic Response Markers. , 2010, , 675-701.		7
214	Hyaluronan activated-metabolism phenotype (HAMP) in pancreatic ductal adenocarcinoma. Oncotarget, 2019, 10, 5592-5604.	1.8	6
215	Surveillance in individuals at high risk of pancreatic cancer: too early to tell?. Gut, 2010, 59, 1005-1005.	12.1	5
216	Genome-Wide Geneâ€"Diabetes and Geneâ€"Obesity Interaction Scan in 8,255 Cases and 11,900 Controls from PanScan and PanC4 Consortia. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 1784-1791.	2.5	5

#	Article	IF	Citations
217	ABO blood group and other genetic variants associated with pancreatic cancer. Genome Medicine, 2010, 2, 39.	8.2	4
218	Polymorphisms in genes related to one-carbon metabolism are not related to pancreatic cancer in PanScan and PanC4. Cancer Causes and Control, 2013, 24, 595-602.	1.8	4
219	Diagnostic Biomarkers. , 2018, , 659-680.		4
220	Editorial: Circulating Biomarkers to Identify Patients With Resectable Pancreatic Cancer. Journal of the National Cancer Institute, 2017, 109, .	6.3	3
221	Screening for Pancreatic Ductal Adenocarcinoma: Are We Asking the Impossible?â€”Letter. Cancer Prevention Research, 2021, 14, 973-974.	1.5	3
222	Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer. Indian Journal of Surgical Oncology, 2011, 2, 9-15.	0.7	2
223	Epigenetic Alterations in Pancreatic Cancer. , 2013, , 185-207.		1
224	Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer. Pancreatology, 2021, 21, 938-941.	1.1	1
225	Diagnostic Biomarkers. , 2017, , 1-22.		0
226	Pancreatic Cancer Genomics, Epigenomics, and Proteomics. , 2008, , 229-252.		0
227	Development of Novel Pancreatic Tumor Biomarkers. , 2010, , 1173-1201.		0